NCT06396091 2025-11-13
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Active not recruiting
Clinical Trials
15 trialsNCT06524973 2025-11-10
Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers
City of Hope Medical Center
Phase NA Recruiting
NCT06576115 2025-11-05
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Recruiting
NCT05078775 2025-07-18
Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer
Faeth Therapeutics
Phase NA Completed
NCT02907099 2025-02-19
Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01954992 2024-12-31
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Eleison Pharmaceuticals LLC.
Phase 3 Recruiting
NCT02677038 2024-10-01
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02826486 2024-08-28
COMBAT
BioLineRx, Ltd.
Phase 2 Completed
NCT01959139 2024-02-09
S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
SWOG Cancer Research Network
Phase 1/2 Completed
NCT02383433 2023-10-23
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT02324543 2023-07-21
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT02194829 2023-04-25
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02562898 2021-05-06
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
University of California, San Francisco
Phase 1/2 Completed
NCT02847000 2019-01-09
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT01729481 2017-07-19
ML22774
Ludwig-Maximilians - University of Munich
Phase 2 Unknown